Trends in uptake of recently approved antiretrovirals within a national healthcare system

HIV Medicine

Volumn 11, Issue 3, 2010, Pages 209-215

  Belperio, P S ^a   Mole, L A ^a   Boothroyd, D B ^a   Backus, L I ^a  

^a VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

Author keywords

Antiretrovirals; HIV AIDS; Protease inhibitor; Uptake; VA healthcare system

Indexed keywords

ANTIRETROVIRUS AGENT; ATAZANAVIR; DARUNAVIR; LOPINAVIR PLUS RITONAVIR; PROTEINASE INHIBITOR; TIPRANAVIR;

ARTICLE; COHORT ANALYSIS; DRUG APPROVAL; DRUG UTILIZATION; FOOD AND DRUG ADMINISTRATION; GEOGRAPHIC DISTRIBUTION; HEALTH CARE FACILITY; HEALTH CARE SYSTEM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; PRESCRIPTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREND STUDY; UNITED STATES; VETERAN;

AMBULATORY CARE FACILITIES; ANTI-RETROVIRAL AGENTS; COHORT STUDIES; DRUG APPROVAL; DRUG PRESCRIPTIONS; ELECTRONIC HEALTH RECORDS; FEMALE; HEALTH FACILITY SIZE; HIV INFECTIONS; HUMANS; MALE; OLIGOPEPTIDES; PHYSICIAN'S PRACTICE PATTERNS; PYRIDINES; PYRONES; RETROSPECTIVE STUDIES; SULFONAMIDES; TIME FACTORS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION; VETERANS;

EID: 75649085681     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2009.00764.x     Document Type: Article

References (22)

1. Petoumenos K. The role of observational data in monitoring trends in antiretroviral treatment and HIV disease stage: results from the Australian HIV observational database. J Clin Virol 2003, 26:209-222.
2. Rates of combination antiretroviral treatment change in Australia, 1997-2000. HIV Med 2002, 3:28-36. Australian HIV Observational Database.
3. Ghani AC, Donnelly CA, Anderson RM. Patterns of antiretroviral use the United States of America: analysis of three observational databases. HIV Med 2003, 4:24-32.
4. Kirk O, Mocroft A, Katzenstein TL. Changes in use of antiretroviral therapy in regions of Europe over time. AIDS 1998, 12:2031-2039.
5. Mocroft A, Sabin CA, Youle M. Changing treatment patterns among patients with HIV. Royal Free Hospital 1987-97. J Acquir Immune Defic Syndr 1998, 18:358-364.
6. Smith SR, Kirking DM. Access and use of medications in HIV disease. Health Serv Res 1999, 34:123-144.
7. Graham NM, Jacobson LP, Kuo V, Chmiel JS, Morganstern H, Zucconi SL. Access to therapy in the Multicenter AIDS cohort study. J Clin Epidemiol 1994, 47:1003-1012.
8. Holodniy M, Hornberger J, Rapoport D. Relationship between antiretroviral prescribing patterns and treatment guidelines in treatment-naïve HIV-1-infected US veterans (1992-2004). J Acquir Immune Defic Syndr 2007, 44:20-29.
9. Sabin CA, Lampe FC, Chaloner C. An audit of antiretroviral treatment use in HIV-infected patients in a London clinic: the limitations of observational databases when auditing antiretroviral treatment use. HIV Med 2003, 4:87-93.
10. Sambamoorthi U, Moynihan PJ, McSpiritt E, Crystal S. Use of protease inhibitors and non-nucleoside reverse transcriptase inhibitors among Medicaid beneficiaries with AIDS. Am J Public Health 2001, 91:1474-1481.
11. Baicker K, Chandra A, Skinner JS. Who you are and where you live: how race and geography affect the treatment of Medicare beneficiaries. Health Aff [suppl web exclusive: VAR33-34]
12. Ashton CM, Petersen NJ, Souchek J. Geographic variations in utilization rates in Veterans Affairs hospitals and clinics. N Engl J Med 1999, 340:32-39.
13. Rogers EM. A prospective and retrospective look at the diffusion model. J Health Commun 2004, 9((Suppl. 1)):13-19.
14. Squires K, Lazzarin A, Gatell JM. Comparison of once-daily atazanavir with efavirenz, each in combination with fixed dose zidovudine and lamivudine, as initial therapy for patients infected with HIV. J Acquir Immune Defic Syndr 2004, 36:1011-1019.
15. Johnson M, Grinsztejn B, Rodriguez C. 96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virologic failures. AIDS 2006, 20:711-718.
16. Sackoff JE, McFarland JW, Shin SS. Trends in prescriptions for highly active antiretroviral therapy in four New York City HIV clinics. JAIDS 2000, 23:178-183.
17. http://www.aidsinfo.nih.gov/contentfiles/AdultandAdolescentGL.pdf, Panel on Antiretroviral Guidelines for Adults and Adolescents., Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. November 3, 2008; 1-139. Available at, (accessed 30 October 2008)
18. Landon BE, Wilson IB, Cohn SE. Physician specialization and antiretroviral therapy for HIV. J Gen Intern Med 2003, 4:233-241.
19. Brosgart CL, Mitchell TF, Coleman RL, Dyner T, Stephenson KE, Abrams DI. Clinical experience and choice of drug therapy for human immunodeficiency virus disease. Clin Infect Dis 1999, 1:23-25.
20. Wilson IB, Landon BE, Ding L. A national study of the relationship of care site HIV specialization to early adoption of highly active antiretroviral therapy. Med Care 2005, 43:12-20.
21. http://www.cdc.gov/hiv/topics/surveillance/resources/slides/urban-nonurban/index.htm, Centers for Disease Control and Prevention., HIV/AIDS surveillance in urban and nonurban areas (through 2006). Available at, (accessed 15 October 2008)
22. Shapiro MF, Morton SC, McCaffrey DF. Variations in the care of HIV-infected adults in the United States: results from the HIV Cost and Services Utilization Study. JAMA 1999, 281:2305-2315.